rs1330 — NUCB2

Intronic NUCB2 variant associated with obesity risk in males, type 2 diabetes risk in females, and colorectal cancer susceptibility — the T allele modestly affects nesfatin-1 signaling across multiple metabolic and oncological contexts

See your personal result for NUCB2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NUCB2 rs1330 — Intronic Nesfatin-1 Variant with Sex-Specific Metabolic and Oncological Effects

Nucleobindin-2 (NUCB2) encodes the precursor protein that is proteolytically cleaved to release nesfatin-111 nesfatin-1
An 82-amino acid neuropeptide that suppresses appetite and modulates energy balance via melanocortin MC3/MC4 receptors and CRF2 — operates independently of the leptin pathway, a neuropeptide with broad roles in appetite suppression, glucose regulation, sleep-wake cycling, and — more recently discovered — cancer biology. The rs1330 variant sits within an intron of NUCB2 on chromosome 11 (GRCh38 position 17,294,482), meaning it does not alter the nesfatin-1 amino acid sequence directly. Instead, its effects are regulatory: the T allele is thought to influence NUCB2 splicing efficiency, transcript stability, or expression levels, though the precise molecular mechanism has not yet been resolved.

The T allele is the minor allele in most populations (~30–39% frequency globally, with notably lower frequency in African populations at ~17%). The reference C/C genotype represents wild-type nesfatin-1 expression; T allele carriers show associations across multiple disease contexts with a consistent direction — higher risk — though with sex-specific patterns that suggest hormonal context shapes how this intronic variant exerts its effects.

The Mechanism

As an intron variant, rs1330 does not change the nesfatin-1 peptide sequence. Its regulatory impact is inferred from its population-level associations. The T allele may alter the efficiency of RNA splicing at one of NUCB2's five transcript variants, reduce mRNA stability, or affect transcription factor binding in an intronic regulatory element — any of which would reduce the amount of functional NUCB2 protein available for cleavage into nesfatin-1. Reduced circulating nesfatin-1 is the common downstream consequence observed in obesity and insulin-resistant states across multiple NUCB2 studies, and the rs1330 T allele likely compounds this deficiency via a cis-regulatory mechanism.

The sex-specific pattern observed in the Zegers et al. obesity study22 Zegers et al. obesity study
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 — where rs1330 associated with obesity only in males — and the reciprocal Li et al. T2D finding33 Li et al. T2D finding
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 in females (OR 1.31–1.42) may reflect estrogen and androgen modulation of NUCB2 expression. Estrogen upregulates nesfatin-1 production in certain hypothalamic circuits, potentially masking the effect of a reduced-expression variant in pre-menopausal women while leaving males more exposed to its impact on appetite and energy balance.

The Evidence

Obesity (males). The Zegers et al. 201144 Zegers et al. 2011
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 case-control study genotyped 1,049 obese and 315 normal-weight Caucasian subjects across eight NUCB2 tagSNPs. Three variants — rs1330, rs214101, and rs757081 — showed association with obesity protection, but only in the male sub-analysis. Linear regression further linked rs1330 to BMI, body weight, and fat-free mass in men. This was the first evidence that NUCB2 intronic variants influence energy homeostasis in humans.

Type 2 diabetes (females). A Chinese Han study by Li et al. (2020)55 Li et al. (2020)
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 genotyped 578 T2DM patients against 1,609 healthy controls and identified rs1330 as significantly associated with T2DM risk in women (OR 1.31–1.42, P<0.05). The variant was also correlated with BMI in the female subpopulation, suggesting its influence spans both adiposity and glucose metabolism in women. No association was detected in men in this cohort — the reverse sex-specificity pattern from the Zegers obesity data.

Colorectal cancer. A Mexican cross-sectional study by Macías-Gómez et al. (2025)66 Macías-Gómez et al. (2025)
Macías-Gómez NM et al. Variants in the neuropeptide gene NUCB2 as a possible biomarker for colorectal cancer. 2025 enrolled 397 CRC patients and 383 healthy controls. The TT genotype at rs1330 was significantly associated with colorectal cancer (OR 2.66, P<0.001), while CT heterozygotes showed an apparent protective pattern (OR 0.61), an unusual non-additive effect possibly reflecting over-dominant heterozygote advantage. Hardy-Weinberg deviation in the CRC group, however, warrants cautious interpretation.

Oral cancer. A Taiwanese cohort study by Yu et al. (2026)77 Yu et al. (2026)
Yu CC et al. Association of NUCB2 genetic variants with the clinicopathological features of oral cancer. 2026 examined four NUCB2 polymorphisms in men with oral cancer. Compared to C/C wild-type, carriage of at least one T allele at rs1330 was associated with elevated risk of disease progression to stage III/IV, particularly in patients aged ≥60 years.

Sleep biology. rs1330 has not been studied directly in sleep GWAS, but the parent gene's sleep-regulatory role is established. In rat models, Vas et al. (2013)88 Vas et al. (2013)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 demonstrated that central nesfatin-1 reduces REM sleep and increases wakefulness, and that hypothalamic NUCB2 expression declines during REM sleep deprivation and rebounds during recovery. Any NUCB2 variant that reduces nesfatin-1 output may therefore modulate sleep architecture, though this remains inferred biology at the rs1330 level.

Practical Implications

For CT and TT carriers, the most actionable implications are in metabolic monitoring and cancer awareness. Given the sex-specific patterns — obesity/BMI associations in males, T2D risk in females — sex-targeted monitoring is appropriate. Dietary interventions that support nesfatin-1 release, particularly high-protein morning meals, are theoretically beneficial but are based on functional biology rather than rs1330-specific trial data.

Interactions

rs1330 was identified in the same study (Zegers et al. 2011) as rs757081 and rs214101 — all three intronic and coding variants in NUCB2 showed male-specific obesity associations together, suggesting they may function as a regulatory haplotype influencing total NUCB2/nesfatin-1 output. Combined carriage of rs1330 T allele and rs757081 C allele (the obesity-risk form at the missense position) may additively reduce effective nesfatin-1 activity through both regulatory and protein-level mechanisms.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Two copies of the reference C allele — standard NUCB2 expression, no additional nesfatin-1 risk from this intronic locus

You carry two copies of the reference C allele at rs1330. This is the most common genotype globally, found in approximately 49% of people. The C/C genotype represents the baseline NUCB2 expression state; published studies use CC as the comparison group when identifying T allele associations with obesity, type 2 diabetes, and cancer risk.

You do not carry the intronic T allele linked to altered NUCB2 regulation, so your nesfatin-1 system is not under additional genetic pressure from this locus.

CT Intermediate

One T allele — intermediate NUCB2 expression state with modest metabolic and cancer risk associations

The sex-specific pattern at rs1330 — obesity/BMI associations dominant in males (Zegers 2011), T2DM risk dominant in females (Li 2020) — suggests that gonadal hormone environments modulate how this intronic NUCB2 variant affects metabolic outcomes. Estrogen upregulates hypothalamic NUCB2 expression, potentially redirecting the T allele's effect from adiposity toward insulin sensitivity in women.

One T allele does not carry the elevated colorectal cancer signal seen in TT homozygotes (OR 2.66 in the Macías-Gómez 2025 study). The heterozygous state at this intronic locus is generally a moderate-risk finding — worth knowing for monitoring orientation, but not an indication of high disease risk in isolation.

TT High Risk

Two copies of the T allele — highest NUCB2 expression impact; associations with obesity, type 2 diabetes, and colorectal cancer risk

The TT genotype is homozygous for the T allele that has been linked — across independent studies in Caucasian, Chinese, and Latin American cohorts — to higher adiposity, diabetes risk, and cancer susceptibility. The consistency across these different endpoints suggests the T allele reduces NUCB2/nesfatin-1 output in a way that broadly affects metabolic homeostasis and potentially tumor surveillance functions.

Nesfatin-1 has been shown to have anti-proliferative effects in several cancer cell lines, and reduced nesfatin-1 has been observed in colorectal cancer patients. The TT OR of 2.66 for CRC from the Macías-Gómez 2025 study, while requiring replication, is large enough to justify proactive colorectal surveillance. The Hardy-Weinberg deviation in that study means this estimate may be imprecise, but the directionality is consistent with the broader nesfatin-1 deficiency hypothesis.

Carriers of multiple NUCB2 risk variants may experience compound impairment of nesfatin-1 at both regulatory and protein levels, representing the lowest effective nesfatin-1 output from NUCB2 genotype.